Drug asset diligence, before the deal gets expensive.
A structured, AI-assisted review of regulatory risk, evidence quality, approval readiness, and hidden value killers — built to sharpen decisions on licensing, acquisition, and investment.
No confidential information required to start the conversation.
- Cross-domain
- Reg · Clin · CMC
- Output
- Executive-ready
- Stage
- Preclinical → NDA
What a review delivers
- An AI-assisted diligence workflow, connected to Alenvo, scoped to your asset and decision timing.
- Structured review of regulatory risk, development gaps, approval readiness, data confidence, and deal-readiness signals.
- Executive outputs: asset verdict, risk map, data gap list, likely FDA questions, value killers, upside drivers, and follow-up priorities.
- Designed to support — not replace — expert regulatory, clinical, legal, and investment judgment.
Traditional asset diligence is slow, fragmented, and expert-bound.
Documents pile up across regulatory, clinical, CMC, safety, and commercial workstreams. Cross-domain risk gets buried in notes. Decisions slip past the window where they matter.
You are not just buying data.
You are buying regulatory probability.
You are buying risk exposure.
You are buying hidden obligations.
An Alenvo-connected, AI-assisted diligence workflow.
Translate fragmented asset data into executive-ready signals across the dimensions that actually move a deal — built to support expert review, not replace it.
- Investment verdict
- Regulatory risk profile
- Approval probability indicators
- Data confidence
- FDA question prediction
- Value killers
- Upside drivers
- Deal strategy considerations
Understand the asset risk before you commit capital.
A short conversation is enough to scope a meaningful diligence review, tailored to your asset stage and decision window.
No confidential information required to start the conversation.